Sumitomo Pharma Co., Ltd.
4506.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | ¥398,832 | ¥314,558 | ¥555,544 | ¥560,035 |
| % Growth | 26.8% | -43.4% | -0.8% | – |
| Cost of Goods Sold | ¥153,437 | ¥126,577 | ¥178,919 | ¥157,127 |
| Gross Profit | ¥245,395 | ¥187,981 | ¥376,625 | ¥402,908 |
| % Margin | 61.5% | 59.8% | 67.8% | 71.9% |
| R&D Expenses | ¥49,865 | ¥112,637 | ¥131,858 | ¥94,903 |
| G&A Expenses | ¥180,605 | ¥429,538 | ¥279,355 | ¥179,559 |
| SG&A Expenses | ¥180,605 | ¥429,538 | ¥339,212 | ¥217,339 |
| Sales & Mktg Exp. | ¥0 | ¥0 | ¥59,857 | ¥37,780 |
| Other Operating Expenses | -¥13,879 | ¥0 | -¥139,327 | ¥30,432 |
| Operating Expenses | ¥216,591 | ¥542,175 | ¥331,743 | ¥342,674 |
| Operating Income | ¥28,804 | -¥354,194 | -¥76,979 | ¥60,234 |
| % Margin | 7.2% | -112.6% | -13.9% | 10.8% |
| Other Income/Exp. Net | -¥11,193 | ¥31,080 | ¥29,059 | ¥22,727 |
| Pre-Tax Income | ¥17,611 | -¥323,114 | -¥47,920 | ¥82,961 |
| Tax Expense | -¥6,024 | -¥8,185 | ¥48,794 | ¥42,361 |
| Net Income | ¥23,634 | -¥314,969 | -¥74,512 | ¥56,413 |
| % Margin | 5.9% | -100.1% | -13.4% | 10.1% |
| EPS | 59.49 | -792.79 | -187.55 | 141.99 |
| % Growth | 107.5% | -322.7% | -232.1% | – |
| EPS Diluted | 59.49 | -792.79 | -187.55 | 141.99 |
| Weighted Avg Shares Out | 397 | 397 | 397 | 397 |
| Weighted Avg Shares Out Dil | 397 | 397 | 397 | 397 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥2,307 | ¥36,022 | ¥32,218 | ¥25,777 |
| Interest Expense | ¥13,500 | ¥4,277 | ¥3,159 | ¥3,050 |
| Depreciation & Amortization | ¥25,562 | ¥37,765 | ¥41,263 | ¥38,348 |
| EBITDA | ¥56,673 | -¥281,072 | -¥3,498 | ¥124,359 |
| % Margin | 14.2% | -89.4% | -0.6% | 22.2% |